Differences in Signal Transduction of Two 5-HT4Receptor Splice Variants: Compound Specificity and Dual Coupling with Gαs- and Gαi/o-Proteins
- 1 January 2002
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 61 (1) , 85-96
- https://doi.org/10.1124/mol.61.1.85
Abstract
This study documents differences in ligand binding and signal transduction properties between the human (h) 5-hydroxytryptamine (5-HT)4a and h5-HT4b receptor splice variants stably expressed in human embryonic kidney 293 cells. The fraction of the [3H]5-HT high-affinity site relative to the whole receptor population measured with [3H]GR113808 was higher for the h5-HT4a isoform (around 0.4) than for the 5-HT4b isoform (around 0.2) and was independent of the level of expression. The potency and efficacy of reference compounds tested for the cAMP response differed slightly but significantly between both variants. Most remarkably, 5-methoxytryptamine and prucalopride were found more potent on the 5-HT4b variant, whereas SDZ-HTF 919 and SB204070 were more potent on the 5-HT4a variant. Guanosine-5′-O-(3-[35S]thio)triphosphate binding on membranes and cAMP assays in whole cells revealed that only the h5-HT4b isoform coupled to Gαi/o-proteins in addition to its well-documented Gαs coupling. In contrast, the h5-HT4a receptor coupled only to Gαs-proteins, however, was able to trigger an increase in the intracellular calcium concentration ([Ca2+]i). The observed [Ca2+]i increase did not occur through inositol phosphate formation and was not sensitive to Bordatella pertussis toxin, forskolin, or 3-isobutyl-1-methylxanthine (pre)treatment but was due to Ca2+ influx from the extracellular environment. Interestingly, the Ca2+ pathway was dependent on high receptor expression levels and was compound-specific, because benzamide-like compounds triggered two to three times higher responses than indoleamines. Taken together, these data provide the first evidence for fine functional differences between C-terminal splice variants of the h5-HT4 receptor, which may contribute to a better understanding of the functional diversity of this receptor class.Keywords
This publication has 36 references indexed in Scilit:
- 5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle.Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 2001
- Mapping of serotonin 5-HT4 receptor mRNA and ligand binding sites in the post-mortem human brainSynapse, 2000
- Structure of the Human Serotonin 5‐HT4 Receptor Gene and Cloning of a Novel 5‐HT4 Splice VariantJournal of Neurochemistry, 2000
- Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5‐HT4 receptor agonist, following oral and intravenous administrationBritish Journal of Clinical Pharmacology, 1999
- Characterization of the 5-HT 4 binding site in human brainJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1998
- Butyrate inhibits colon carcinoma cell growth through two distinct pathwaysSurgery, 1998
- Cloning, Expression, and Pharmacology of Four Human 5‐Hydroxytryptamine4 Receptor Isoforms Produced by Alternative Splicing in the Carboxyl TerminusJournal of Neurochemistry, 1998
- Molecular and functional characterization of a 5‐HT4 receptor cloned from human atriumFEBS Letters, 1997
- [3H]5-Hydroxytryptamine labels the agonist high affinity state of the cloned rat 5-HT4 receptorEuropean Journal of Pharmacology, 1996
- Pharmacological comparison between [3H]GR 113808 binding sites and functional 5-HT4 receptors in neuronsEuropean Journal of Pharmacology, 1996